Skip to main content

From the helm: Immutep’s (ASX:IMM) Executive Director & CEO Marc Voigt

Sophia Mavridis
April 6, 2022

In this instalment of our From the helm series, Bell Direct’s Sophia Mavridis speaks to Immutep’s (ASX:IMM) Executive Director and CEO, Marc Voigt.

Global biotechnology company, Immutep is a leading developer of autoimmune and cancer immunotherapy treatments. The business has been gaining a lot of attention lately as its lead product is in its late-stage clinical trials for metastatic breast cancer.

In this video Marc discusses:

  • (0:40) What IMM does and its key strength in the market
  • (1:27) The impact of the FDA’s recent feedback on its lead product
  • (2:53) IMM’s collaborations with big pharma names like Pfizer & Merck
  • (4:03) When to expect data from its current clinical trials
  • (5:10) What’s coming up for IMM

Note: This interview was filmed on 22 March 2022.

Weekly Wrap 16 February

Sophia Mavridis
February 16, 2024

Morning Bell 16 February

Sam Kanaan
February 16, 2024

Morning Bell 15 February

Sam Kanaan
February 15, 2024

Morning Bell 14 February

Sam Kanaan
February 14, 2024

Morning Bell 13 February

Grady Wulff
February 13, 2024

Morning Bell 12 February

Grady Wulff
February 12, 2024

Weekly Wrap 9 February

Grady Wulff
February 9, 2024

Morning Bell 9 February

Sam Kanaan
February 9, 2024

Morning Bell 8 February

Sam Kanaan
February 8, 2024